These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34645477)

  • 1. Recovery capital among people receiving treatment for opioid use disorder with buprenorphine.
    Parlier-Ahmad AB; Terplan M; Svikis DS; Ellis L; Martin CE
    Harm Reduct J; 2021 Oct; 18(1):103. PubMed ID: 34645477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender.
    Parlier-Ahmad AB; Radic M; Svikis DS; Martin CE
    Drug Alcohol Depend; 2022 Mar; 232():109337. PubMed ID: 35123364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.
    Parlier-Ahmad AB; Pugh M; Martin CE
    J Racial Ethn Health Disparities; 2022 Aug; 9(4):1557-1567. PubMed ID: 34254271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 6. Substance use severity as a predictor for receiving medication for opioid use disorder among adolescents: An analysis of the 2019 TEDS.
    Welsh JW; Sitar SI; Hunter BD; Godley MD; Dennis ML
    Drug Alcohol Depend; 2023 May; 246():109850. PubMed ID: 36989708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program.
    Reed MK; Smith KR; Ciocco F; Hass RW; Cox AL; Kelly EL; Weinstein LC
    Subst Abuse Treat Prev Policy; 2023 Jan; 18(1):4. PubMed ID: 36641478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
    Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Recovery Capital Among Patients Receiving Buprenorphine Treatment for Opioid Use Disorder in a Telehealth Setting.
    Rowe C; Williams AR; Bisaga A
    Subst Use Addctn J; 2024 Sep; ():29767342241283174. PubMed ID: 39347714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.
    Andraka-Christou B; Totaram R; Randall-Kosich O
    Subst Abus; 2022; 43(1):415-424. PubMed ID: 34214400
    [No Abstract]   [Full Text] [Related]  

  • 14. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences among persons entering medication treatment for opioid use disorder in the community.
    Di Paola A; Taweh N; Biondi BE; Forray A; Frank CA; Shaw A; Springer SA
    Am J Addict; 2022 Sep; 31(5):390-395. PubMed ID: 35652902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder.
    Cook RR; Jaworski EN; Hoffman KA; Waddell EN; Myers R; Korthuis PT; Vergara-Rodriguez P
    Subst Abus; 2023 Oct; 44(4):301-312. PubMed ID: 37842910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Exploratory Study of Sex and Gender Differences in Demographic, Psychosocial, Clinical, and Substance Use Treatment Characteristics of Patients in Outpatient Opioid Use Disorder Treatment with Buprenorphine.
    Parlier-Ahmad AB; Martin CE; Radic M; Svikis D
    Transl Issues Psychol Sci; 2021 Jun; 7(2):141-153. PubMed ID: 34541257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees.
    Hoffman LA; Vilsaint CL; Kelly JF
    J Subst Abuse Treat; 2021 Dec; 131():108464. PubMed ID: 34098288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.